Shares of Lupin Ltd. are currently up 2.5% on reporting Q1FY20 results.
In the quarter ended June 2019, sales came in at Rs4,355cr compared to Rs4,326cr in Q4FY19 (up 0.7% qoq) and Rs3,775cr in Q1FY19 (up 15.4% yoy).
EBITDA for the quarter was Rs932cr compared to Rs711cr in Q1FY19 up 31.1% yoy.
Consequently, net profits for the quarter came in at Rs303.1cr vs. Rs202.8cr in Q1FY19, up 49.5% yoy.
The co’s investment in Research and Development for the quarter was Rs378.5cr, which accounts for 8.7% of sales.
Lupin received approvals for 5 ANDAs from the USFDA during the quarter.
Cumulative ANDA filings with the USFDA stood at 422 as of June 30, 2019, with the company having received 270 approvals to date.
The Company now has 40 First-to-Files (FTF) filings including 15 exclusive FTF opportunities. Cumulative DMF filings stands at 204 as of June 30, 2019.
Commenting on the results, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, “We are pleased with the robust all-round performance in our key markets, marking a healthy start for the fiscal year. This year is critical as we are committed to delivering on our strategic growth drivers, including commercialization of Complex Generics, ramp-up of our Specialty business and delivering on operational and cost efficiencies. Regulatory compliance remains a top organizational priority and we are making steady progress.”